BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 35147737)

  • 1. GPC3-targeted immunoPET imaging of hepatocellular carcinomas.
    An S; Zhang D; Zhang Y; Wang C; Shi L; Wei W; Huang G; Liu J
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2682-2692. PubMed ID: 35147737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ImmunoPET imaging of multiple myeloma with [
    Wang C; Chen Y; Hou YN; Liu Q; Zhang D; Zhao H; Zhang Y; An S; Li L; Hou J; Huang G; Liu J; Zhao YJ; Wei W
    Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2749-2760. PubMed ID: 33543326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiofluorinated GPC3-Binding Peptides for PET Imaging of Hepatocellular Carcinoma.
    Li Y; Zhang J; Gu J; Hu K; Huang S; Conti PS; Wu H; Chen K
    Mol Imaging Biol; 2020 Feb; 22(1):134-143. PubMed ID: 31044341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging the expression of glypican-3 in hepatocellular carcinoma by PET.
    Wang Z; Han YJ; Huang S; Wang M; Zhou WL; Li HS; Wang QS; Wu HB
    Amino Acids; 2018 Feb; 50(2):309-320. PubMed ID: 29204748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Site-Specifically Conjugated Single-Domain Antibody Successfully Identifies Glypican-3-Expressing Liver Cancer by Immuno-PET.
    Fayn S; King AP; Gutsche NT; Duan Z; Buffington J; Olkowski CP; Fu Y; Hong J; Sail D; Baidoo KE; Swenson RE; Cheloha RW; Ho M; Choyke PL; Escorcia FE
    J Nucl Med; 2023 Jul; 64(7):1017-1023. PubMed ID: 36997331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Annotating BCMA Expression in Multiple Myelomas.
    Wei W; Zhang Y; Zhang D; Liu Q; An S; Chen Y; Huang G; Liu J
    Mol Pharm; 2022 Oct; 19(10):3492-3501. PubMed ID: 34843261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ImmunoPET imaging of Trop2 expression in solid tumors with nanobody tracers.
    Huang W; Liang C; Zhang Y; Zhang D; An S; Wu Q; Li J; Zhao H; Wang C; Cui J; Bao Z; Huang G; Wei W; Liu J
    Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):380-394. PubMed ID: 37792026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imaging of hepatocellular carcinoma patient-derived xenografts using ⁸⁹Zr-labeled anti-glypican-3 monoclonal antibody.
    Yang X; Liu H; Sun CK; Natarajan A; Hu X; Wang X; Allegretta M; Guttmann RD; Gambhir SS; Chua MS; Cheng Z; So SK
    Biomaterials; 2014 Aug; 35(25):6964-71. PubMed ID: 24836949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and preclinical evaluation of a novel probe [
    Mo C; Sun P; Liang H; Chen Z; Wang M; Fu L; Huang S; Tang G
    Bioorg Chem; 2024 Jun; 147():107352. PubMed ID: 38640719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glypican-3-targeting F(ab')2 for 89Zr PET of hepatocellular carcinoma.
    Sham JG; Kievit FM; Grierson JR; Chiarelli PA; Miyaoka RS; Zhang M; Yeung RS; Minoshima S; Park JO
    J Nucl Med; 2014 Dec; 55(12):2032-7. PubMed ID: 25359880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The development of a Glypican-3-specific binding peptide using
    Qin Y; Cheng S; Li Y; Zou S; Chen M; Zhu D; Gao S; Wu H; Zhu L; Zhu X
    Biomater Sci; 2020 Oct; 8(20):5656-5665. PubMed ID: 32896851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma.
    Sham JG; Kievit FM; Grierson JR; Miyaoka RS; Yeh MM; Zhang M; Yeung RS; Minoshima S; Park JO
    J Nucl Med; 2014 May; 55(5):799-804. PubMed ID: 24627434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low glucose metabolism in hepatocellular carcinoma with GPC3 expression.
    Li YC; Yang CS; Zhou WL; Li HS; Han YJ; Wang QS; Wu HB
    World J Gastroenterol; 2018 Jan; 24(4):494-503. PubMed ID: 29398870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ImmunoPET imaging of human CD8
    Zhao H; Wang C; Yang Y; Sun Y; Wei W; Wang C; Wan L; Zhu C; Li L; Huang G; Liu J
    J Nanobiotechnology; 2021 Feb; 19(1):42. PubMed ID: 33563286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glypican-3: A promising biomarker for hepatocellular carcinoma diagnosis and treatment.
    Zhou F; Shang W; Yu X; Tian J
    Med Res Rev; 2018 Mar; 38(2):741-767. PubMed ID: 28621802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions.
    Wang HL; Anatelli F; Zhai QJ; Adley B; Chuang ST; Yang XJ
    Arch Pathol Lab Med; 2008 Nov; 132(11):1723-8. PubMed ID: 18976006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and
    Ma XH; Wang S; Liu SY; Chen K; Wu ZY; Li DF; Mi YT; Hu LB; Chen ZW; Zhao XM
    World J Gastroenterol; 2019 Jun; 25(24):3030-3043. PubMed ID: 31293339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical development of novel PD-L1 tracers and first-in-human study of [
    Zhang Y; Cao M; Wu Y; Malih S; Xu D; Yang E; Younis MH; Lin W; Zhao H; Wang C; Liu Q; Engle JW; Rasaee MJ; Guan Y; Huang G; Liu J; Cai W; Xie F; Wei W
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel Glypican-3-Binding Peptide for in Vivo Hepatocellular Carcinoma Fluorescent Imaging.
    Zhu D; Qin Y; Wang J; Zhang L; Zou S; Zhu X; Zhu L
    Bioconjug Chem; 2016 Mar; 27(3):831-9. PubMed ID: 26850086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ImmunoPET Imaging of CD47 with VHH-Derived Tracers in Pancreatic Cancers.
    Liang C; Huang W; Zhang Y; Zhang D; An S; Wu Q; Zhao H; Wang C; Huang G; Wei W; Liu J
    Mol Pharm; 2023 Aug; 20(8):4184-4195. PubMed ID: 37403817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.